|
Market Closed -
Nasdaq
07:00:00 15/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 153.54 USD | +3.80% |
|
+4.56% | +25.09% |
| 15/10 | Vir Biotechnology Shares Jump on Gilead Cancer Collaboration | DJ |
| 15/10 | Vir Biotechnology, Gilead Sciences to Develop Dual-Masked T-Cell Engagers for Solid Tumors | MT |
Company Valuation: Gilead Sciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 91,081 | 107,677 | 100,942 | 115,118 | 152,281 | 190,383 | - | - |
| Change | - | 18.22% | -6.25% | 14.04% | 32.28% | 25.02% | - | - |
| Enterprise Value (EV) 1 | 118,530 | 126,522 | 118,665 | 131,838 | 169,585 | 210,386 | 202,923 | 196,148 |
| Change | - | 6.74% | -6.21% | 11.1% | 28.63% | 24.06% | -3.55% | -3.34% |
| P/E | 14.7x | 23.6x | 18x | 243x | 18.1x | -44.9x | 19.1x | 17.5x |
| PBR | 4.32x | 5.05x | 4.48x | 5.98x | 6.73x | 13.4x | 9.48x | 7.22x |
| PEG | - | -0.9x | 0.8x | -2.7x | 0x | 0x | -0x | 2.01x |
| Capitalization / Revenue | 3.34x | 3.95x | 3.72x | 4x | 5.17x | 6.2x | 5.8x | 5.51x |
| EV / Revenue | 4.34x | 4.64x | 4.38x | 4.59x | 5.76x | 6.85x | 6.18x | 5.68x |
| EV / EBITDA | 8.12x | 8.86x | 9.01x | 11.7x | 10.6x | 26.6x | 11.2x | 10.5x |
| EV / EBIT | 9.45x | 10.4x | 11.3x | 15.5x | 12.9x | 64.3x | 12.7x | 11.5x |
| EV / FCF | 11x | 15.2x | 16x | 12.8x | 17.9x | -399x | 14.1x | 14.1x |
| FCF Yield | 9.12% | 6.59% | 6.25% | 7.82% | 5.58% | -0.25% | 7.09% | 7.07% |
| Dividend per Share 2 | 2.84 | 2.92 | 3 | 3.08 | 3.16 | 3.293 | 3.352 | 3.015 |
| Rate of return | 3.91% | 3.4% | 3.7% | 3.33% | 2.57% | 2.14% | 2.18% | 1.96% |
| EPS 2 | 4.93 | 3.64 | 4.5 | 0.38 | 6.78 | -3.423 | 8.056 | 8.758 |
| Distribution rate | 57.6% | 80.2% | 66.7% | 811% | 46.6% | -96.2% | 41.6% | 34.4% |
| Net sales 1 | 27,305 | 27,281 | 27,116 | 28,754 | 29,443 | 30,724 | 32,816 | 34,529 |
| EBITDA 1 | 14,598 | 14,283 | 13,177 | 11,287 | 15,953 | 7,898 | 18,072 | 18,689 |
| EBIT 1 | 12,548 | 12,180 | 10,484 | 8,520 | 13,193 | 3,274 | 15,981 | 17,060 |
| Net income 1 | 6,225 | 4,592 | 5,665 | 480 | 8,510 | -4,257 | 10,268 | 10,910 |
| Net Debt 1 | 27,449 | 18,845 | 17,723 | 16,720 | 17,304 | 20,003 | 12,540 | 5,765 |
| Reference price 2 | 72.61 | 85.85 | 81.01 | 92.37 | 122.74 | 153.54 | 153.54 | 153.54 |
| Nbr of stocks (in thousands) | 1,254,384 | 1,254,244 | 1,246,042 | 1,246,266 | 1,240,680 | 1,239,955 | - | - |
| Announcement Date | 1/2/22 | 2/2/23 | 6/2/24 | 11/2/25 | 10/2/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -43.22x | 6.62x | 25.76x | 2.23% | 183B | |
| 33.19x | 12.03x | 25.3x | 0.59% | 1,040B | |
| 36.75x | 6.12x | 17.02x | 2.15% | 599B | |
| 34.92x | 8.07x | 16.64x | 2.53% | 485B | |
| 109.67x | 5.8x | 24.85x | 2.4% | 350B | |
| 19.42x | 4.74x | 11.78x | 2.78% | 345B | |
| 20.05x | 5.27x | 12.97x | 3.02% | 272B | |
| 20.63x | 4.17x | 11.97x | 2.12% | 244B | |
| 26.21x | 6.79x | 12.15x | 2.44% | 223B | |
| 11.42x | 4.17x | 8.63x | 4.44% | 170B | |
| Average | 26.90x | 6.38x | 16.71x | 2.47% | 391.28B | |
| Weighted average by Cap. | 32.96x | 7.58x | 18.58x | 2.04% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GILD Stock
- Valuation Gilead Sciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
